Cxcl-8 Predicts Hbeag Seroconversion And Post Treatment Flares In Chronic Hepatitis B (Chb) Patients Treated With Interferon (Ifn)-Alfa

23.3%; p 0.017). 3 patients on ST had HBsAg loss compared with MT (1) by 52 weeks. Factors associated with HBsAg loss included ST, higher baseline ALT and female sex. No major therapeutic adverse effects requiring treatment discontinuation. Conclusions: Sequential therapy using tenofovir and PEG-IFN a2b may provide rapid and higher biochemical and virological response in selected HBeAg(+) CHB patients. Long-term clinical trials are needed to assess for sustained durable response.